{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:08Z","timestamp":1786119368469,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There are isolated reports of Guillain-Barr\u00e9 syndrome (GBS) after receiving vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To determine the rates and characteristics of GBS after administration of vaccination in United States<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We used data for 1990 to 2005 from the Vaccine Adverse Event Reporting System, which is a cooperative program of the Centers for Disease Control and Prevention and the US Food and Drug Administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      There were 1000 cases (mean age, 47 years) of GBS reported after vaccination in the United States between 1990 and 2005. The onset of GBS was within 6 weeks in 774 cases, &gt;6 weeks in 101, and unknown in 125. Death and disability after the event occurred in 32 (3.2%) and 167 (16.7%) subjects, respectively. The highest number (n = 632) of GBS cases was observed in subjects receiving influenza vaccine followed by hepatitis B vaccine (n = 94). Other vaccines or combinations of vaccines were associated with 274 cases of GBS. The incidence of GBS after influenza vaccination was marginally higher in subjects &lt;65 years compared with those \u226565 years (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.09); for hepatitis vaccine, the incidence was significantly higher (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001) in the &lt;65 group. Death was more frequent in subjects \u226565 years compared with those &lt;65 years (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our results suggest that vaccines other than influenza vaccine can be associated with GBS. Vaccination-related GBS results in death or disability in one fifth of affected individuals, which is comparable to the reported rates in the general GBS population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cnd.0b013e3181aaa968","type":"journal-article","created":{"date-parts":[[2009,8,30]],"date-time":"2009-08-30T03:12:32Z","timestamp":1251601952000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":38,"title":["Guillain-Barr\u00e9 Syndrome after Vaccination in United States: Data From the Centers for Disease Control and Prevention\/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005)"],"prefix":"10.1097","volume":"11","author":[{"given":"Nizar","family":"Souayah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abu","family":"Nasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Fareed K","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan I","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20240808","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977.","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"R2-1-20240808","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/oxfordjournals.aje.a115973","article-title":"Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group.","volume":"133","author":"Safranek","year":"1991","journal-title":"Am J Epidemiol"},{"key":"R3-1-20240808","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/archinte.166.12.1301","article-title":"No association between immunization and Guillain-Barre syndrome in the United Kingdom, 1992 to 2000.","volume":"166","author":"Hughes","year":"2006","journal-title":"Arch Intern Med"},{"key":"R4-1-20240808","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1016\/j.vaccine.2007.03.053","article-title":"Guillain-Barre syndrome after vaccination in United States a report from the CDC\/FDA Vaccine Adverse Event Reporting System.","volume":"25","author":"Souayah","year":"2007","journal-title":"Vaccine"},{"key":"R5-1-20240808","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199812173392501","article-title":"The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines.","volume":"339","author":"Lasky","year":"1998","journal-title":"N Engl J Med"},{"key":"R6-1-20240808","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1001\/jama.292.20.2478","article-title":"Guillain-Barre syndrome following influenza vaccination.","volume":"292","author":"Haber","year":"2004","journal-title":"JAMA"},{"key":"R7-1-20240808","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1067\/mpd.2001.111165","article-title":"Risk of Guillain-Barre syndrome after measles-mumps-rubella vaccination.","volume":"138","author":"Patja","year":"2001","journal-title":"J Pediatr"},{"key":"R8-1-20240808","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain-Barre syndrome.","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"key":"R9-1-20240808","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/jaut.1999.0346","article-title":"Vaccination and autoimmunity-vaccinosis: a dangerous liaison?","volume":"14","author":"Shoenfeld","year":"2000","journal-title":"J Autoimmun"},{"key":"R10-1-20240808","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S1521-6616(03)00046-9","article-title":"Influenza vaccination and Guillain Barre syndrome small star, filled.","volume":"107","author":"Geier","year":"2003","journal-title":"Clin Immunol"},{"key":"R11-1-20240808","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1001\/jama.294.21.2744","article-title":"Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004.","volume":"294","author":"Sejvar","year":"2005","journal-title":"JAMA"},{"key":"R12-1-20240808","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1001\/jama.298.18.2155","article-title":"Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States.","volume":"298","author":"Roush","year":"2007","journal-title":"JAMA"},{"key":"R13-1-20240808","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00007890-199903150-00019","article-title":"Influenza vaccination in liver transplant recipients.","volume":"67","author":"Burbach","year":"1999","journal-title":"Transplantation"},{"key":"R14-1-20240808","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/lt.20864","article-title":"Guillain-Barre syndrome triggered by influenza vaccination in a recipient of liver transplant on FK506.","volume":"12","author":"Moon","year":"2006","journal-title":"Liver Transpl"},{"key":"R15-1-20240808","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1016\/j.vaccine.2009.01.077","article-title":"Influenza vaccination in patients with cirrhosis and in liver transplant recipients.","volume":"27","author":"Gaeta","year":"2009","journal-title":"Vaccine"},{"key":"R16-1-20240808","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","article-title":"Incidence of adamantine resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.","volume":"366","author":"Bright","year":"2005","journal-title":"Lancet"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00131402-200909000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:04:32Z","timestamp":1786039472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00131402-200909000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0b013e3181aaa968","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}